Scynexis(SCYX)
JERSEY CITY, NJ
BiotechnologyFocus: Small Molecules
Scynexis is a life sciences company focused on Small Molecules.
Infectious DiseasesRespiratory
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Non-interventional study
Vulvovaginal CandidiasisClinical Trials (1)
NCT05908682Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
N/AIbrexafungerp
Fungal DiseaseClinical Trials (1)
NCT05668429ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects
Phase 1Placebo
Chronic Hepatitis CClinical Trials (1)
NCT01290965Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients
Phase 1[14C]-Ibrexafungerp
Fungal InfectionClinical Trials (1)
NCT04307082ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects
Phase 1Ibrexafungerp
Vulvovaginal CandidiasisClinical Trials (1)
NCT06954493Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
Phase 1Phase 1
Clinical Trials (1)
NCT04092725Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects
Phase 1Phase 1
Clinical Trials (1)
NCT04092751Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects
Phase 1Fluconazole
Candida VulvovaginitisClinical Trials (1)
NCT03253094Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
Phase 2SCY-078
Vulvovaginal CandidiasisClinical Trials (1)
NCT02679456Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis
Phase 2SCY-078
MycosesClinical Trials (1)
NCT02244606Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
Phase 2Placebo
Hepatitis C InfectionClinical Trials (1)
NCT01265511Study of SCY-635, Pegasys and Copegus in Hepatitis C
Phase 2Phase 2
Clinical Trials (1)
NCT03672292Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Phase 2Ibrexafungerp
Vulvovaginal CandidiasisClinical Trials (1)
NCT05399641Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
Phase 3Ibrexafungerp
Candida VulvovaginitisClinical Trials (1)
NCT03734991Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)
Phase 3SCY-078
Candidiasis, InvasiveClinical Trials (1)
NCT03363841Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
Phase 3SCY-078
Candidiasis, InvasiveClinical Trials (1)
NCT05178862A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
Phase 3Fluconazole Tablet
Recurrent Vulvovaginal CandidiasisClinical Trials (1)
NCT04029116Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
Phase 3Ibrexafungerp
Candida VulvovaginitisClinical Trials (1)
NCT03987620Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
Phase 3Ibrexafungerp
Invasive CandidiasisClinical Trials (1)
NCT03059992Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 19 clinical trials
SEC Filings: 2 available
Financials (FY2025)
Revenue
$4M97%
R&D Spend
$26M(705%)15%
Net Income
-$21MCash
$16M